Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ Rx Comparative Research Partners Include CMS, NIH, FDA, VA, McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS administrator says NIH can develop comparative evidence based on clinical trial databases and keep CMS apprised of drugs being studied. Speakers at AHRQ comparative research “town hall” point to public, private and international purchasers that could provide comparative drug information.

You may also be interested in...



Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec

Pressure is growing for greater disclosure of study results, which may shift industry R&D, Schering compliance VP Saunders says. Former DoJ attorney Bentivoglio suggests that disclosure requirements would include cost-effectiveness data.

Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec

Pressure is growing for greater disclosure of study results, which may shift industry R&D, Schering compliance VP Saunders says. Former DoJ attorney Bentivoglio suggests that disclosure requirements would include cost-effectiveness data.

AHRQ Rx Comparisons Should Focus On Existing Literature, Not Clinical Trials, McClellan Says

Clinical trials take too much time and money, CMS Administrator McClellan says. Programs mandated under Medicare Rx law, such as the chronic care improvement pilot and the Part B replacement drug demo, will provide clinical data to evaluate comparative effectiveness, he says.

Topics

UsernamePublicRestriction

Register

PS059494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel